Pafuramidine gets OD status for PCP
USA-based drugmaker Immtech Pharmaceuticals says that the Food and Drug Administration has a granted its drug, pafuramidine (DB289), Orphan Drug designation for use in the treatment of Pneumocystis jiroveci pneumonia (PCP), an opportunistic infection common in HIV/AIDS patients and other immunosuppressed individuals.
The firm explained that pafuramidine, the active component in its drug candidate pafuramidine maleate, is currently in Phase III assessment as a treatment for the infection in patients with HIV/AIDS. The company added that previous clinical trials indicated that the drug has similar efficacy to trimethoprim sulfamethoxazole (TMP-SMX), the current standard therapy for PCP.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze